241 results on '"Wang, Eunice S."'
Search Results
2. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
3. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
4. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia
5. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
6. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
7. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
8. How I treat: secondary acute myeloid leukemia
9. Acute myeloid leukemia with LRRFIP1::FGFR1 rearrangement and a complex karyotype
10. KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress
11. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
12. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
13. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML
14. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
15. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
16. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
17. Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes
18. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML
19. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
20. Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
21. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
22. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
23. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
24. Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
25. Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone
26. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia
27. A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia
28. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
29. Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis
30. A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia
31. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias
32. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
33. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
34. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia
35. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801
36. Clinical and functional significance of circular RNAs in cytogenetically normal AML
37. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
38. Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States
39. A precision medicine classification for treatment of acute myeloid leukemia in older patients
40. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
41. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
42. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia
43. Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy
44. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
45. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
46. Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
47. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
48. AML-465 Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement
49. AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies
50. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.